Considering that cardiovascular events are increased in patients with a low estimated glomerular filtration rate (eGFR) [12], the possibility exists that increased FGF23 levels mediate an adverse cardiovascular outcome among patients with end-stage renal disease. This evidence concerns the gene FGF23 and chronic kidney disease.